pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

831 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT783Endpoints585BioPharma Dive224onclive165BioSpace59Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • ICON audit finds overstated revenue; Secretome and Psilera raise cash
    👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1%…
    Endpoints · 1mo ago↗ source
  • #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
    In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the m…
    Endpoints · 1mo ago↗ source
  • Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm
    Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture…
← prev
page 19 of 34
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
    Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies…
    Endpoints · 2mo ago↗ source
  • China gene editing startup YolTech raises $70M to move CRISPR therapies forward
    One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their…
    Endpoints · 2mo ago↗ source
  • Oura pushes deeper into healthcare services as part of new ring launch
    Alongside the debut of Oura's smaller Ring 5, the wearables company on Thursday unveiled its plans to help users integrate health records and translate their ring’s findings into medical care. Ou…
    Endpoints · 2mo ago↗ source
  • AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
    AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...
    Endpoints · 2mo ago↗ source
  • GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
    GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four mark…
    Endpoints · 2mo ago↗ source
  • AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
    Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a f…
    Endpoints · 2mo ago↗ source
  • TrumpRx adds hundreds of generic medicines to site
    The Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines. President Donald Trump…
    Endpoints · 2mo ago↗ source
  • Another Paragon offshoot chooses reverse merger, this time for migraine drugs
    They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the…
    Endpoints · 2mo ago↗ source
  • Acceleron leaders and Westlake jumpstart new IPF biotech
    After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A roun…
    Endpoints · 2mo ago↗ source
  • The state of consumer health
    On Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on ...
    Endpoints · 2mo ago↗ source
  • Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
    Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early ...
    Endpoints · 2mo ago↗ source
  • Wave aims for monthly dosing with RNA editing treatment for AATD
    Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. P…
    Endpoints · 2mo ago↗ source
  • Full-Life Technologies raises $150M; Quince's reboot with pulmonary drug
    Plus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round…
    Endpoints · 2mo ago↗ source
  • Nourish raises $100M for virtual nutrition care
    Nourish, a telehealth platform that arranges virtual appointments with nutritionists, just raised a new round that bumped its valuation to $1.75 billion, according to a person familiar with the mat…
    Endpoints · 2mo ago↗ source
  • Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
    Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer. The biotech…
    Endpoints · 2mo ago↗ source
  • BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
    BioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the EN…
    Endpoints · 2mo ago↗ source
  • Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report
    The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning doctors against writing new prescripti…
    Endpoints · 2mo ago↗ source
  • FDA's unreleased Covid vaccine deaths report is published by lawmaker
    An analysis launched by former FDA leaders to look into claims of pediatric deaths related to Covid-19 vaccines was published by a Republican lawmaker, months after the agency's self-imposed deadli…
    Endpoints · 2mo ago↗ source
  • Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
    As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as $2.2 billion. Para…
    Endpoints · 2mo ago↗ source
  • Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China
    Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improve…
    Endpoints · 2mo ago↗ source
  • Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
    An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the pat…
    Endpoints · 2mo ago↗ source
  • The Supreme Court won't take up drugmakers' IRA cases
    The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca…
    Endpoints · 2mo ago↗ source